2.5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML Injection [Opdivo Qvantig]
- RxCUI
- 2728492
- RxNorm name
- 2.5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML Injection [Opdivo Qvantig]
- Display name
- 2.5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML Injection [Opdivo Qvantig]
- Full name
- 2.5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML Injection [Opdivo Qvantig]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:05
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761381 | Opdivo Qvantig | nivolumab and hyaluronidase-nvhy | 351(a) | Rx | 2026-08-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| OPDIVO QVANTIG | NIVOLUMAB AND HYALURONIDASE-NVHY | E.R. Squibb & Sons, L.L.C. | 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b | 2026-05-12 | Warnings, Adverse reactions | 2728492 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b | OPDIVO Qvantig 300 MG / 5,000 UNT in 2.5 ML Injection [PSN] · 2.5 ML hyaluronidase-nvhy 2000 UNT/ML / nivolumab-nvhy 120 MG/ML Injection [Opdivo Qvantig] [SBD] · Opdivo Qvantig (nivolumab-hyaluronidase-nvhy 300 MG / 5,000 UNT) per 2.5 ML Injection [SY] | 3 | 8 | These highlights do not include all the information needed to use OPDIVO QVANTIG safely and effectively. See full prescribing information for OPDIVO QVANTIG. OPDIVO QVANTIG™ (nivolumab and hyaluronidase-nvhy) injection, for subcutaneous use. Initial U.S. Approval: 2024 | 20260512 |